Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。